Meta-analysis of pucotenlimab shows improved outcomes across multiple solid tumors
New analysis shows pucotenlimab improves outcomes for several solid tumor types.
This meta-analysis evaluated pucotenlimab (HX008) in patients with gastric, gastroesophageal junction, triple-negative breast cancer, melano…
A new analysis of pucotenlimab shows significantly improved outcomes versus control for patients with gastric cancer, triple-negative breast…
AI-mediated ultrasonic radiomics shows potential for triple-negative breast cancer diagnosis and prognosis
AI tools show promise for triple negative breast cancer
This review of research progress examines AI-mediated ultrasonic radiomics for patients with triple-negative breast cancer (TNBC). The techn…
New AI methods using ultrasound images may help doctors better identify and predict how triple negative breast cancer might progress.
Review of immunotherapy innovations for triple-negative breast cancer survival
New Hope for Tough-to-Treat Breast Cancer
This narrative review examines immunotherapy innovations, including immune checkpoint inhibitors and combination strategies, for patients wi…
This approach may change how doctors treat one of the hardest forms of breast cancer.
Pembrolizumab plus chemotherapy improved event-free survival in Japanese patients with untreated locally advanced triple-negative breast cancer
An Immune-Boosting Drug Raises Breast Cancer Survival Odds Before Surgery
This phase 3 randomized controlled trial subgroup analysis included 76 Japanese patients with untreated locally advanced triple-negative bre…
Japanese women with aggressive early breast cancer saw higher 5-year survival odds when an immune-boosting drug was added to chemotherapy be…
Talazoparib monotherapy in neoadjuvant triple-negative breast cancer reveals BRN2-driven resistance mechanisms.
Why Some BRCA Breast Cancers Shrug Off Talazoparib Before Surgery
This Phase II neoadjuvant trial evaluated talazoparib in patients with germline mutant breast tumors. Mechanistic analysis showed that BRN2 …
Some BRCA breast cancers shrink under talazoparib, but others find hidden escape routes that let them ignore the drug before surgery.
Meta-analysis finds immunotherapy plus chemotherapy improves outcomes in triple-negative breast cancer
New Combo Boosts Survival for Triple-Negative Breast Cancer
A meta-analysis of triple-negative breast cancer patients found that adding immunotherapy to chemotherapy improved pathological complete res…
Adding immune checkpoint inhibitors to chemotherapy improves survival and tumor response for triple-negative breast cancer patients.
Neoadjuvant chemotherapy plus sintilimab improved response rates versus chemotherapy alone in 61 patients with triple-negative breast cancer.
Combination therapy improved response rates in a small study of triple-negative breast cancer patients.
This retrospective cohort study evaluated 61 patients with triple-negative breast cancer (TNBC) receiving neoadjuvant therapy at a single ce…
Adding the immunotherapy drug sintilimab to standard chemotherapy boosted response rates and slowed tumor growth in triple-negative breast c…
Pyroptosis-related gene signature predicts prognosis in triple-negative breast cancer patients.
Can a gene signature predict survival for triple-negative breast cancer patients?
This observational cohort study analyzed data from TCGA and GEO databases, validated in an independent GEO cohort and 48 clinical samples, t…
A genetic warning system in triple-negative breast cancer tumors can predict which patients face a higher risk of the cancer returning.